An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta

Pyroglutamate amyloid beta3–42 (pGlu-Abeta3–42), a highly amyloidogenic and neurotoxic form of Abeta, is N-terminally truncated to form a pyroglutamate and has recently been proposed as a key target for immunotherapy. Optimized ACI-24, a vaccine in development for the treatment and prevention of Alz...

Descripción completa

Detalles Bibliográficos
Autores principales: Vukicevic, M., Fiorini, E., Siegert, S., Carpintero, R., Rincon-Restrepo, M., Lopez-Deber, P., Piot, N., Ayer, M., Rentero, I., Babolin, C., Bravo-Veyrat, S., Giriens, V., Morici, C., Beuzelin, M., Gesbert, A., Rivot, S., Depretti, S., Donati, P., Streffer, J., Pfeifer, A., Kosco-Vilbois, M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037369/
https://www.ncbi.nlm.nih.gov/pubmed/35479516
http://dx.doi.org/10.1093/braincomms/fcac022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037369/
https://www.ncbi.nlm.nih.gov/pubmed/35479516
http://dx.doi.org/10.1093/braincomms/fcac022

Ejemplares similares